Different pharmacologic agents have been evaluated in the treatment of Chronic Fatigue Syndrome (CFS), albeit with moderate efficacy. Among the compounds thought to present with potential to be efficacious in CFS patients stands out low-dose amisulpride, a substituted benzamide that has been shown to be an useful treatment for conditions which exhibit some overlap with CFS such as dysthymia and somatoform disorders. We thus recruited forty non-depressed CFS patients that were randomized to receive either amisulpride 25mg bid, or fluoxetine 20mg uid; all subjects were un-blinded to the treatment regimen. At the time of enrollment in the study and after twelve weeks of treatment, enrolled subjects completed the Krupp Fatigue Severity Scale, the Hospital Anxiety and Depression Scale and a visual analog scale focused on pain and bodily discomfort. Moreover, all subjects were evaluated by a clinician, blinded to the treatment regimen, using the Clinical Global Impression Severity Scale. Our data revealed a significant improvement both in self-report, and observer-based measures for the amisulpride-treated, but not for the fluoxetine-treated patients. Amisulpride-treated subjects also presented with a significant reduction of somatic complaints, while the amisulpride effect on anxiety and mood levels was not significant. Both drugs were equally well tolerated. Summing up, we showed a positive symptomatic effect of amisulpride, compared to SSRI treatment, in a group of non-depressed CSF patients on self-report and on observer-based measures of fatigue and somatic complaints. If confirmed by larger, blinded studies, amisulpride thus could represent an effective approach to this difficult-to-treat condition.

Pardini, M., Guida, S., Primavera, A., Krueger, F., Cocito, L., Emberti, L. (2011). Amisulpride vs. fluoxetine treatment of Chronic Fatigue Syndrome: A pilot study. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 21(3), 282-286 [10.1016/j.euroneuro.2010.10.008].

Amisulpride vs. fluoxetine treatment of Chronic Fatigue Syndrome: A pilot study

EMBERTI, LEONARDO
2011-01-01

Abstract

Different pharmacologic agents have been evaluated in the treatment of Chronic Fatigue Syndrome (CFS), albeit with moderate efficacy. Among the compounds thought to present with potential to be efficacious in CFS patients stands out low-dose amisulpride, a substituted benzamide that has been shown to be an useful treatment for conditions which exhibit some overlap with CFS such as dysthymia and somatoform disorders. We thus recruited forty non-depressed CFS patients that were randomized to receive either amisulpride 25mg bid, or fluoxetine 20mg uid; all subjects were un-blinded to the treatment regimen. At the time of enrollment in the study and after twelve weeks of treatment, enrolled subjects completed the Krupp Fatigue Severity Scale, the Hospital Anxiety and Depression Scale and a visual analog scale focused on pain and bodily discomfort. Moreover, all subjects were evaluated by a clinician, blinded to the treatment regimen, using the Clinical Global Impression Severity Scale. Our data revealed a significant improvement both in self-report, and observer-based measures for the amisulpride-treated, but not for the fluoxetine-treated patients. Amisulpride-treated subjects also presented with a significant reduction of somatic complaints, while the amisulpride effect on anxiety and mood levels was not significant. Both drugs were equally well tolerated. Summing up, we showed a positive symptomatic effect of amisulpride, compared to SSRI treatment, in a group of non-depressed CSF patients on self-report and on observer-based measures of fatigue and somatic complaints. If confirmed by larger, blinded studies, amisulpride thus could represent an effective approach to this difficult-to-treat condition.
2011
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/42 - IGIENE GENERALE E APPLICATA
English
Dopamine Antagonists; Fatigue Syndrome, Chronic; Female; Fluoxetine; Humans; Male; Pilot Projects; Psychiatric Status Rating Scales; Serotonin Uptake Inhibitors; Single-Blind Method; Sulpiride; Treatment Outcome
Pardini, M., Guida, S., Primavera, A., Krueger, F., Cocito, L., Emberti, L. (2011). Amisulpride vs. fluoxetine treatment of Chronic Fatigue Syndrome: A pilot study. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 21(3), 282-286 [10.1016/j.euroneuro.2010.10.008].
Pardini, M; Guida, S; Primavera, A; Krueger, F; Cocito, L; Emberti, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Emberti_Gialloreti_Chronic_Fatigue_Syndrome (2).pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 185.71 kB
Formato Adobe PDF
185.71 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/140811
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 14
social impact